Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 19:10:937794.
doi: 10.3389/fpubh.2022.937794. eCollection 2022.

Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: A cross-sectional study

Elias Ali Yesuf  1 , Abanoub Riad  2   3 , Ahmad Sofi-Mahmudi  4   5 , Morankar Sudhakar  6 , Addisalem Mekonnen  7 , Selamawit Endalkachew  8 , Feyissa Mama  7 , Semira Muhidin  9 , Bethelhem Ayele  10 , Mohammed Yahya  11 , Abduselam Usman  12 , Jemal Abafita  13 , Miloslav Klugar  3   14
Affiliations

Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: A cross-sectional study

Elias Ali Yesuf et al. Front Public Health. .

Abstract

Introduction: Ethiopia is the second most populous country in Africa. Ethiopia received most of its COVID-19 vaccines through donations. The Oxford AstraZeneca vaccine is the first to be donated to Ethiopia by the COVAX facility. Healthcare workers were the priority population that received the Oxford AstraZeneca COVID-19 vaccine. However, there was no nationwide study on the safety of the vaccine in Ethiopia. This study aimed to measure the prevalence and predictors of self-reported side effects of the Oxford AstraZeneca vaccine.

Materials and methods: The study employed a cross-sectional design. A sample of healthcare workers who took Oxford AstraZeneca COVID-19 vaccine was drawn from four regions of Ethiopia; namely, Amhara, Oromia, Somali, and Southwest. Data were collected on sociodemographic characteristics, medical anamnesis, COVID-19 related anamnesis, and COVID-19 vaccine anamnesis via telephone interview. Descriptive and inferential analyses were done. The software, IBM SPSS Statistics v21.0, was used for analyses of data.

Results: Out of 384 people, 346 responded (response rate: 90.1%). Female accounted for 34.1% of the respondents. The mean age of the respondents was 31.0 years (Standard Deviation (SD) = 7.4). Nurses accounted for 43.7% of the respondents. The prevalence of at least one local- and systemic-side effect was 50.6 and 44.5%, respectively. The most frequent local- and systemic- side effect were injection site pain and headache, respectively. Both types of side effects mostly subsided in the first 3 days. A third of healthcare workers with side effects took at least one medication. Paracetamol followed by diclofenac sodium were taken by healthcare workers to overcome side effects. There was no independent predictor of local side effect. After controlling for age and chronic diseases, the odds of healthcare workers with COVID-19 like symptoms to experience systemic side effects was 1.38 (Confidence Interval (CI): 1.04-1.82) times more than that of healthcare workers without COVID-19 like symptoms.

Conclusions: The prevalence of local- and systemic-side effects of the Oxford AstraZeneca COVID-19 vaccine was modest. As the symptoms were mostly common in the first 3 days, it is preferable to monitor healthcare workers at least in the first 3 days following the administration of the vaccine.

Keywords: Africa; COVID-19 vaccine; Ethiopia; Healthcare workers; Oxford AstraZeneca; side effects.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study setting of self-reported side effects of COVID-19 vaccines, Ethiopia, 2021.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization. Listings of WHO's Response to COVID-19. (2022). Available online at: https://www.who.int/news/item/29-06-2020-covidtimeline (accessed July 6, 2022).
    1. Koo JR, Cook AR, Park M, Sun Y, Sun H, Lim JT, et al. . Articles interventions to mitigate early spread of SARS-CoV-2 in Singapore : a modeling study. Lancet Infect Dis. (2020) 20:1–11. 10.1016/S1473-3099(20)30162-6 - DOI - PMC - PubMed
    1. Chowdhury R, Luhar S, Khan N, Choudhury SR, Matin I. Long-term strategies to control COVID - 19 in low and middle - income countries : an options overview of community - based, non - pharmacological interventions. Eur J Epidemiol. (2020) 35:743–8. 10.1007/s10654-020-00660-1 - DOI - PMC - PubMed
    1. Agarwal A, Rochweng B, Lamontagne F, Siemieniuk RA, Agoritsas T, Askie L, et al. . A living WHO guideline on drugs for COVID-19. BMJ. (2020) 370:1–19. 10.1136/bmj.m3379 - DOI - PubMed
    1. Kashte S, Gulbake A, El-Amin III SF, Gupta A. COVID-19 vaccines: rapid development, implications, challenges and future prospects. Hum Cell. (2021) 34:711–33. 10.1007/s13577-021-00512-4 - DOI - PMC - PubMed

Substances